129 related articles for article (PubMed ID: 38712513)
21. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
[TBL] [Abstract][Full Text] [Related]
23. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
[TBL] [Abstract][Full Text] [Related]
25. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
26. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
[TBL] [Abstract][Full Text] [Related]
27. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
[TBL] [Abstract][Full Text] [Related]
28. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors.
Wada N; Takahashi T; Kurokawa Y; Nakajima K; Nishida T; Koh M; Akamaru Y; Motoori M; Kimura Y; Tanaka K; Miyazaki Y; Makino T; Yamasaki M; Eguchi H; Doki Y
Surg Today; 2021 Sep; 51(9):1506-1512. PubMed ID: 33570662
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
[No Abstract] [Full Text] [Related]
32. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study.
Seesing MF; Tielen R; van Hillegersberg R; van Coevorden F; de Jong KP; Nagtegaal ID; Verhoef C; de Wilt JH;
Eur J Surg Oncol; 2016 Sep; 42(9):1407-13. PubMed ID: 27038995
[TBL] [Abstract][Full Text] [Related]
33. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
Chacón M; Eleta M; Espindola AR; Roca E; Méndez G; Rojo S; Pupareli C
Future Oncol; 2015; 11(6):953-64. PubMed ID: 25760976
[TBL] [Abstract][Full Text] [Related]
34. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Yeh CN; Wang SY; Tsai CY; Chen YY; Liu CT; Chiang KC; Chen TW; Liu YY; Yeh TS
Int J Surg; 2017 Mar; 39():30-36. PubMed ID: 28110026
[TBL] [Abstract][Full Text] [Related]
35. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
Farag S; van Coevorden F; Sneekes E; Grunhagen DJ; Reyners AKL; Boonstra PA; van der Graaf WT; Gelderblom HJ; Steeghs N
Eur J Cancer; 2017 Nov; 86():318-325. PubMed ID: 29073582
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
Cheng CT; Tsai CY; Yeh CN; Chiang KC; Chen YY; Wang SY; Chen TW; Tseng JH; Jung SM; Chen TC; Yeh TS
Anticancer Res; 2014 Nov; 34(11):6617-25. PubMed ID: 25368266
[TBL] [Abstract][Full Text] [Related]
37. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
[TBL] [Abstract][Full Text] [Related]
38. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Dematteo RP; Ballman KV; Antonescu CR; Maki RG; Pisters PW; Demetri GD; Blackstein ME; Blanke CD; von Mehren M; Brennan MF; Patel S; McCarter MD; Polikoff JA; Tan BR; Owzar K;
Lancet; 2009 Mar; 373(9669):1097-104. PubMed ID: 19303137
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]